製品番号: HY-B1751

キニジン

(別名: Quinidine (15% dihydroquinidine))

24 Cited Publications

カスタマーレビュー

Based on 24 publication(s) in Google Scholar

Quinidine (15% dihydroquinidine) is an orally active antiarrhythmic agent. Quinidine (15% dihydroquinidine) reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine (15% dihydroquinidine) exerts sustained block and open-channel block effects on I_K(f). Quinidine (15% dihydroquinidine) alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine (15% dihydroquinidine) can be used in studies related to uterine sarcoma and seizures.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.36%
CAS 番号: 56-54-2
分子式: C₂₀H₂₄N₂O₂
分子量:324.42

保管条件:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Quinidine (15% dihydroquinidine) 構造式

CAS 番号: 56-54-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (24)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Caspase 3

PARP アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	2.2 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	[PMID: 10820137]
CHO	IC₅₀	6.4 μM Compound: quinidine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
CHO	IC₅₀	2.67 μM Compound: Quinidine	Inhibition of human ERG expressed in CHO cells by patch plate method Inhibition of human ERG expressed in CHO cells by patch plate method	[PMID: 26640981]
HEK293	IC₅₀	113.8 μM Compound: quinidine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HEK293	IC₅₀	16600 nM Compound: Quinidine	Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA	[PMID: 21300721]
HEK293	IC₅₀	19.82 μM Compound: Quinidine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	11.2 μM Compound: quinidine	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	23.4 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells	[PMID: 10027858]
Hepatocyte	IC₅₀	240 μM Compound: 14 Quinidine	Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes	[PMID: 15225721]
Huh-7	CC₅₀	50.75 μM Compound: GNF-Pf-5459	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
LLC-PK1	IC₅₀	10 μM Compound: Quinidine	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	10 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	13 μM Compound: Quinidine	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	13 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	5.6 μM Compound: Quinidine	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	5.6 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
NIH-3T3-G185	IC₅₀	1 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	18.8 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	33.9 μM Compound: Quinidine	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
ScN2a	IC₅₀	5 μM Compound: quinidine	Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation	[PMID: 17850126]
Ventricular myocyte	IC₅₀	15600 nM Compound: Quinidine	Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes	[PMID: 21300721]
Ventricular myocyte	IC₅₀	10 μM Compound: Quinidine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	15.6 μM Compound: Quinidine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
WI-38	IC₅₀	11.28 μg/mL Compound: 1b	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 23816880]
WI-38	IC₅₀	34.81 μM Compound: QND	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 26063305]

体外実験

Quinidine (15% dihydroquinidine) (10 μM; 24 h) potentiates Paclitaxel (HY-B0015)-induced cytotoxicity in P-gp-positive MES-SA/DX5 uterine sarcoma cells (reducing paclitaxel IC₅₀ to 80.56 nM) but does not alter paclitaxel cytotoxicity in P-gp-negative MES-SA uterine sarcoma cells^[1].
Quinidine (15% dihydroquinidine) (10 μM; 24 h) significantly increases the sub-G1 apoptotic portion in paclitaxel-treated P-gp-positive MES-SA/DX5 uterine sarcoma cells, enhancing paclitaxel-induced apoptosis^[1].
Quinidine (15% dihydroquinidine) inhibits the in vitro metabolism of Debrisoquine in rat liver microsomes, with lower potency than observed in human liver microsomes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

P-gp-negative MES-SA uterine sarcoma cells, P-gp-positive MES-SA/DX5 uterine sarcoma cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Did not significantly alter the cytotoxicity of paclitaxel in MES-SA cells, with paclitaxel IC₅₀ remaining comparable to paclitaxel alone (19 nM vs. 18 nM).
Strongly potentiated paclitaxel-induced cytotoxicity in MES-SA/DX5 cells, reducing the IC₅₀ of paclitaxel from 13851 nM to 81 nM.
Showed no significant cytotoxicity up to 100 μM in either cell line.\nShowed concentration-dependent cytotoxicity with docetaxel against MES-SA cells.
Enhanced docetaxel-induced cytotoxicity in MES-SA/DX5 cells more potently than hydrocinchonine, alongside cinchonine.
Showed no significant cytotoxicity up to 100 μM in either cell line.

Cell Cycle Analysis^[1]

Cell Line:

P-gp-positive MES-SA/DX5 uterine sarcoma cells (paclitaxel-treated)
Concentration:

10 μM
Incubation Time:

24 h
Result:

Significantly increased the sub-G1 apoptotic portion (G₀ = 27.19) in paclitaxel-treated MES-SA/DX5 cells, whereas paclitaxel alone induced minimal sub-G1 accumulation (G₀ = 0.05).

体内実験

Quinidine (15% dihydroquinidine) (80 mg/kg; p.o.; single administration) potently inhibits amphetamine ring hydroxylation in male Lewis rats, reducing the excretion of p-hydroxyamphetamine to 7.2% and 24.1% of the control group levels at 24 h and 48 h, respectively, while increasing the late-phase excretion of amphetamine to 542% of the control group level^[3].
Quinidine (15% dihydroquinidine) (10-30 mg/kg; intraperitoneal injection; single administration) significantly elevates the threshold of pentylenetetrazol-induced tonic convulsions in male NMRI mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Lewis (male, 175-225 g)^[3]
Dosage:

80 mg/kg
Administration:

p.o.; single dose
Result:

Reduced urinary excretion of p-hydroxyamphetamine to 7.2% of vehicle-control levels in the 0-24 h collection period.
Reduced urinary excretion of p-hydroxyamphetamine to 24.1% of vehicle-control levels in the 24-48 h collection period.
Increased amphetamine excretion to 542% of control levels in the 24-48 h period.
Excreted an average of 0.40 μmol p-hydroxyamphetamine and 7.80 μmol amphetamine in the 0-24 h period.
Excreted an average of 3.60 μmol amphetamine and a significantly reduced amount of p-hydroxyamphetamine relative to controls in the 24-48 h period.
Achieved total combined excretion of amphetamine and p-hydroxyamphetamine over 48 h equal to 79.7% of the administered dose, which was not significantly different from control groups.

Animal Model:

NMRI (male, 5-6 weeks old, 25-30 g)^[4]
Dosage:

10 mg/kg; 20 mg/kg; 30 mg/kg
Administration:

i.p.; single dose
Result:

Did not alter the pentylenetetrazole threshold dose for onset of myoclonic twitch.
Significantly increased the pentylenetetrazole threshold dose for onset of tonic hind limb extension compared to saline-treated controls (p < 0.05).

化学情報

CAS 番号 56-54-2
性状 Solid
分子量 324.42
分子式 C₂₀H₂₄N₂O₂
Color White to off-white
SMILES

C=C[C@H]1C[N@](CC[C@H]1C2)[C@@]2([H])[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34
別名

Quinidine (15% dihydroquinidine)
Structure Classification
- Alkaloids
- Quinoline Alkaloids
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Publications (24)

All Flow CytometryWBBio/Physico-chemical AssayRT-PCR

Sort by:

Journal Impact Factor

Nat Commun

Small molecule in situ resin capture provides a compound first approach to natural product discovery. [Abstract]

2024 Jun 19;15(1):5230. PMID: 38898025
Adv Sci (Weinh)

LPS-Induced Mitochondrial Damage via SLC41A1-Mediated Magnesium Ion Efflux Leads to the Pyroptosis of Dental Stem Cells. [Abstract]

2025 Aug 19:e05666. PMID: 40831212

Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 19:e05666. [Abstract]

Quinidine rescued [Mg^2⁺]_i levels in LPS‐treated or TRPM7‐silenced DPSCs and SCAP.
J Hazard Mater

Stereostructure-activity mechanism of cyproconazole by cytochrome P450 in rat liver microsomes: A combined experimental and computational study. [Abstract]

2021 Aug 15:416:125764. PMID: 33827004

Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2021 Aug 15:416:125764. [Abstract]

Effects of CYP enzymes inhibitors on metabolic rates of cyproconazole stereoisomers in the in vitro incubation mixtures with RLMs. The asterisks (*) indicates the significant difference in metabolic rates under inhibition compared to the control.
Environ Int

A potential biomarker of isofenphos-methyl in humans: A chiral view. [Abstract]

2019 Jun:127:694-703. PMID: 30991225

Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Environ Int. 2019 Jun:127:694-703. [Abstract]

CYP2D6 has contributed in the enantioselectivity of IFP and ICPO because the EF value of the KND-supplemented group follows a doseeffect relationship and the difference in the EF values was over 10% relative to the DMSO control group.
Anal Chem

A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC-HRMS for Doping Control. [Abstract]

2025 Nov 18;97(45):25158-25167. PMID: 41202118
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
J Med Chem

Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. [Abstract]

2020 Oct 8;63(19):11085-11099. PMID: 32886512
Environ Pollut

Assessing environmental and human health risks: Insight from the enantioselective metabolism and degradation of fenpropidin. [Abstract]

2024 Aug 15:355:124214. PMID: 38801883
Pharmaceutics

Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy. [Abstract]

2025 Mar 26;17(4):423. PMID: 40284418
J Agric Food Chem

Enantioselective Metabolic Mechanism and Metabolism Pathway of Pydiflumetofen in Rat Liver Microsomes: In Vitro and In Silico Study. [Abstract]

2022 Mar 2;70(8):2520-2528. PMID: 35184556
Cell Mol Life Sci

The contrasting effects of two antimalarial drugs on insulin secretion. [Abstract]

2025 Nov 25;82(1):419. PMID: 41288707
RSC Adv

Identification of key transporters mediating uptake of aconitum alkaloids into the liver and kidneys and the potential mechanism of detoxification by active ingredients of liquorice. [Abstract]

2019 May 23;9(28):16136-16146. PMID: 35521419
Front Pharmacol

Eye Drops of Metformin Prevents Fibrosis After Glaucoma Filtration Surgery in Rats via Activating AMPK/Nrf2 Signaling Pathway. [Abstract]

2020 Jul 31:11:1038. PMID: 32903813

Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31:11:1038. [Abstract]

Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Quinidine treatment by western blot.

Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31:11:1038. [Abstract]

Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Atropine/Quinidine treatment by qRT-PCR.
Cell Calcium

MONNA alleviates MPTP-induced Parkinson's disease in zebrafish by activating TFEB dependently on ER Calcium. [Abstract]

2026 Mar:134:103125. PMID: 41637953
Virol J

KCNE4 is a crucial host factor for Orf virus infection by mediating viral entry. [Abstract]

2024 Aug 8;21(1):181. PMID: 39118175
J Anim Sci

Polyamines protect boar sperm from oxidative stress in vitro. [Abstract]

2022 Apr 1;100(4):skac069. PMID: 35247050
Andrology

Pharmacological inhibition of KSper impairs flagellar pH homeostasis of human spermatozoa. [Abstract]

2025 Oct;13(7):1805-1815. PMID: 39498893
AAPS J

Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. [Abstract]

2021 Jun 28;23(4):91. PMID: 34181150
Food Chem Toxicol

The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk. [Abstract]

2022 Nov:169:113431. PMID: 36116547
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Pharmacol Res Perspect

Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats. [Abstract]

2021 Oct;9(5):e00879. PMID: 34628723
Pharmacol Res Perspect

Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]

2020 Apr;8(2):e00575. PMID: 32266794
Eur J Drug Metab Pharmacokinet

Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans. [Abstract]

2022 Sep;47(5):639-652. PMID: 35733077
Chemosphere

A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. [Abstract]

2021 Dec:284:131347. PMID: 34323809

溶剤 & 溶解度

体外:

DMSO : ≥ 50 mg/mL (154.12 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 14.29 mg/mL (44.05 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0824 mL

15.4121 mL

30.8242 mL

5 mM

0.6165 mL

3.0824 mL

6.1648 mL

10 mM

0.3082 mL

1.5412 mL

3.0824 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (290 KB)
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Lee SY, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 2011 Aug;26(4):424-31. [Content Brief]

[2]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991;103(3):1807-1813. [Content Brief]

[3]. Moody DE, et al. Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol. 1990;14(5):311-317. [Content Brief]

[4]. Jamali H, et al. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020;729:134988. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.0824 mL	15.4121 mL	30.8242 mL	77.0606 mL
	5 mM	0.6165 mL	3.0824 mL	6.1648 mL	15.4121 mL
	10 mM	0.3082 mL	1.5412 mL	3.0824 mL	7.7061 mL
	15 mM	0.2055 mL	1.0275 mL	2.0549 mL	5.1374 mL
	20 mM	0.1541 mL	0.7706 mL	1.5412 mL	3.8530 mL
	25 mM	0.1233 mL	0.6165 mL	1.2330 mL	3.0824 mL
	30 mM	0.1027 mL	0.5137 mL	1.0275 mL	2.5687 mL
	40 mM	0.0771 mL	0.3853 mL	0.7706 mL	1.9265 mL
DMSO	50 mM	0.0616 mL	0.3082 mL	0.6165 mL	1.5412 mL
	60 mM	0.0514 mL	0.2569 mL	0.5137 mL	1.2843 mL
	80 mM	0.0385 mL	0.1927 mL	0.3853 mL	0.9633 mL
	100 mM	0.0308 mL	0.1541 mL	0.3082 mL	0.7706 mL

Keywords

Quinidine (15% dihydroquinidine)

24 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

キニジン

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Quinidine (15% dihydroquinidine)

PARP アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

キニジン

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Quinidine (15% dihydroquinidine)

PARP アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Quinidine (15% dihydroquinidine) 関連分類

HY-B1751 関連分類